Revvity announced a value-added distribution agreement with SCIEX, a global leader in life science analytical technologies, which is aimed at advancing mass spectrometry solutions in Revvity’s newborn screening products.
The anticipated solution combines Revvity’s expertise and resources with SCIEX’s innovative mass spectrometry solutions, the company’s say. With this agreement, Revvity hopes to further help laboratories identify newborn babies with a range of rare disorders, from lysosomal storage disorders to amino acid disorders.
Mass spectrometry is a fundamental tool in expanded newborn screening and has seen remarkable growth over the years. Revvity will combine SCIEX mass spectrometers with Revvity’s NeoBase 2 and NeoLSD reagents to support this growth even further by enhancing the robustness and precision of mass spectrometry analyses for newborn screening.
Expanded newborn screening techniques such as mass spectrometry are fundamental in discovering babies with rare, but treatable conditions, such as lysosomal storage conditions, as early as possible. Currently, over 40 conditions can be screened for using mass spectrometry, and this collaboration hopes to advance the precision and robustness of this screening.
Further reading: Revvity Launches as Science-Based Solutions Company
“Revvity is committed to advancing newborn screening and helping give babies a better start in life,” says Petra Furu, general manager, reproductive health, Revvity. “This capability will help provide our customers with the best options for their expanded screening programs by combining precise instrumentation with groundbreaking reagents.”
